MY160435A - A novel antiviral peptide against avian influenza virus h9n2 - Google Patents

A novel antiviral peptide against avian influenza virus h9n2

Info

Publication number
MY160435A
MY160435A MYPI20082061A MYPI20082061A MY160435A MY 160435 A MY160435 A MY 160435A MY PI20082061 A MYPI20082061 A MY PI20082061A MY PI20082061 A MYPI20082061 A MY PI20082061A MY 160435 A MY160435 A MY 160435A
Authority
MY
Malaysia
Prior art keywords
influenza virus
avian influenza
phages
aiv
peptides
Prior art date
Application number
MYPI20082061A
Other languages
English (en)
Inventor
Datin Paduka Dr Khatijah Mohd Yusof Prof
Prof Dr Abdul Rahman Omar Assoc
Aini Ideris Zprof
Rajik Mohamed
Original Assignee
Univ Putra Malaysia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Putra Malaysia filed Critical Univ Putra Malaysia
Priority to MYPI20082061A priority Critical patent/MY160435A/en
Priority to PCT/MY2009/000071 priority patent/WO2009151313A1/en
Priority to DK09762696.4T priority patent/DK2300492T3/da
Priority to EP09762696.4A priority patent/EP2300492B1/en
Priority to JP2011513436A priority patent/JP5647111B2/ja
Priority to US12/995,889 priority patent/US8883480B2/en
Publication of MY160435A publication Critical patent/MY160435A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI20082061A 2008-06-12 2008-06-12 A novel antiviral peptide against avian influenza virus h9n2 MY160435A (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
MYPI20082061A MY160435A (en) 2008-06-12 2008-06-12 A novel antiviral peptide against avian influenza virus h9n2
PCT/MY2009/000071 WO2009151313A1 (en) 2008-06-12 2009-06-10 A novel antiviral peptide against avian influenza virus h9n2
DK09762696.4T DK2300492T3 (da) 2008-06-12 2009-06-10 Hidtil ukendt antiviralt peptid mod aviær influenza h9n2
EP09762696.4A EP2300492B1 (en) 2008-06-12 2009-06-10 A novel antiviral peptide against avian influenza virus h9n2
JP2011513436A JP5647111B2 (ja) 2008-06-12 2009-06-10 トリインフルエンザウイルスｈ９ｎ２に対する新規な抗ウイルスペプチド
US12/995,889 US8883480B2 (en) 2008-06-12 2009-06-10 Antiviral peptide against avian influenza virus H9N2

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MYPI20082061A MY160435A (en) 2008-06-12 2008-06-12 A novel antiviral peptide against avian influenza virus h9n2

Publications (1)

Publication Number Publication Date
MY160435A true MY160435A (en) 2017-03-15

Family

ID=41416902

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI20082061A MY160435A (en) 2008-06-12 2008-06-12 A novel antiviral peptide against avian influenza virus h9n2

Country Status (6)

Country Link
US (1) US8883480B2 (enExample)
EP (1) EP2300492B1 (enExample)
JP (1) JP5647111B2 (enExample)
DK (1) DK2300492T3 (enExample)
MY (1) MY160435A (enExample)
WO (1) WO2009151313A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013540425A (ja) * 2010-08-03 2013-11-07 ザ ユニバーシティ オブ ワシントン スルー イッツ センター フォー コマーシャライゼーション インフルエンザ感染の治療および制限のうち少なくとも一方を行うためのポリペプチド
CN102830225B (zh) * 2012-09-24 2014-06-04 中国动物疫病预防控制中心 一种源于禽流感病毒自然弱毒株的血凝素和免疫抗原
MY184269A (en) * 2015-11-27 2021-03-30 Viramatix Sdn Bhd Broad-spectrum anti-influenza virus therapeutic peptides
KR20200012894A (ko) 2017-05-26 2020-02-05 비라매틱스 에스디엔 비에이치디 펩타이드 및 항바이러스제로서의 이의 용도
WO2020006494A1 (en) 2018-06-29 2020-01-02 Fred Hutchinson Cancer Research Center Cell-stored barcoded deep mutational scanning libraries and uses of the same
CN109487011B (zh) * 2019-01-07 2022-03-01 广西壮族自治区兽医研究所 用于检测h5、h7和h9以及9个na亚型aiv的引物组合及其应用
CN109487012B (zh) * 2019-01-07 2020-09-22 广西壮族自治区兽医研究所 用于检测9个na亚型aiv的引物组合及其应用
CN109628641B (zh) * 2019-01-07 2022-03-01 广西壮族自治区兽医研究所 用于检测h7以及5个na亚型aiv的引物组合及其应用
US11821111B2 (en) 2019-11-15 2023-11-21 Fred Hutchinson Cancer Center Barcoded influenza viruses and deep mutational scanning libraries including the same

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
NZ506987A (en) * 1998-03-17 2003-01-31 Sangamo Biosciences Inc Nucleic acid binding proteins
WO2000059932A1 (fr) * 1999-03-31 2000-10-12 Otsuka Pharmaceutical Co., Ltd. Peptides se liant a l'hemagglutinine du virus de la grippe
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2007022425A2 (en) * 2005-08-16 2007-02-22 Hawaii Biotech, Inc. Influenza recombinant subunit vaccine
JP5093100B2 (ja) * 2006-03-13 2012-12-05 学校法人慶應義塾 インフルエンザ感染阻害ペプチド、インフルエンザウイルス感染阻害剤、リポソーム、インフルエンザ予防・治療剤
KR20090031938A (ko) * 2006-07-05 2009-03-30 더 스크립스 리서치 인스티튜트 방향성 진화로 촉매 작용을 최적화시킨 키메라 징크 핑거 리컴비나제
US8778847B2 (en) * 2007-06-13 2014-07-15 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Immunogenic peptides of influenza virus
EP2174957B1 (en) * 2007-06-15 2016-03-16 Xiamen University Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof

Also Published As

Publication number Publication date
EP2300492B1 (en) 2014-06-04
JP2011522561A (ja) 2011-08-04
EP2300492A4 (en) 2012-03-14
JP5647111B2 (ja) 2014-12-24
US8883480B2 (en) 2014-11-11
EP2300492A1 (en) 2011-03-30
US20110135676A1 (en) 2011-06-09
DK2300492T3 (da) 2014-09-01
WO2009151313A1 (en) 2009-12-17

Similar Documents

Publication Publication Date Title
MY160435A (en) A novel antiviral peptide against avian influenza virus h9n2
BR112014006390A2 (pt) anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano
WO2007089753A3 (en) Monoclonal antibodies binding to avian influenza virus subtype h5 haemagglutinin and uses thereof
EA200970255A1 (ru) Связывающие молекулы человека, способные нейтрализовать вирус гриппа h5n1, и их применение
MX2011000768A (es) Anticuerpos neutralizantes del virus anti-influenza a y usos de los mismos.
NZ596032A (en) Human binding molecules capable of neutralizing influenza virus h3n2 and uses thereof
EA201491051A1 (ru) Вакцины против вируса гриппа и их применения
MX2013015323A (es) Polipeptidos de fusion de serpina y metodos de uso de los mismos.
NZ597692A (en) Anti-IGF antibodies
CL2007001488A1 (es) Anticuerpo humano o humanizado anti-integrina alfa5beta1; acido nucleico que lo codifica; vector y celula huesped que lo comprenden; procedimiento de produccion; composicion farmaceutica que lo comprende; y su uso para prevenir o tratar trastornos asociados con la integrina.
EA201590545A1 (ru) Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией
MX2013007716A (es) Sistemas de expresion.
MX348152B (es) Anticuerpo monoclonal humano con especificidad para el virus del dengue serotipo 1 proteina e y sus usos.
WO2009035412A8 (en) Monoclonal antibodies specific to hemagglutinin from influenza virus h5-subtype and uses thereof
PE20120532A1 (es) ANTICUERPOS ANTI-ActRIIB
CU24058B1 (es) Antagonistas de pcsk9
CO6440535A2 (es) Antagonistas especificos del receptor fgf-r4
ATE552846T1 (de) Verbesserter grippeimpfstoff
WO2010036970A3 (en) Influenza vaccines, antigens, compositions, and methods
CL2008002092A1 (es) Conjugado que contiene dos o mas peptidos antifusogenicos y un anticuerpo anti-cd-4; metodo de produccion; composicion farmaceutica que lo comprende; polipeptidos antifusogenicos y uso del conjugado para tratar infecciones viricas.
MX2019007921A (es) Nuevos agentes de union a ha.
HRP20150664T1 (hr) Antikancerogeni fuzijski protein
EA201001045A1 (ru) Модифицированный вирус гриппа
BR112014028130A2 (pt) Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos
López-Martínez et al. Inhibition of influenza A virus infection in vitro by peptides designed in silico